LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

571.31 3.63

Buy Sell

Overview

Share price change

24h

Current

Min

552.42

Max

587.79

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-75M -114M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+3.49% upside

Market Stats
By TradingEconomics
Market Cap	3.7B 13B
Previous open	567.68
Previous close	571.31

News Sentiment

By Acuity

28%

72%

91 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 gru 2025, 22:02 UTC

Earnings

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 gru 2025, 21:46 UTC

Earnings

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 gru 2025, 23:52 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 gru 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 gru 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 gru 2025, 23:20 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 gru 2025, 23:15 UTC

Earnings

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 gru 2025, 22:59 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 gru 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 gru 2025, 22:40 UTC

Earnings

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 gru 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 gru 2025, 22:06 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 gru 2025, 22:02 UTC

Earnings

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 gru 2025, 22:00 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 gru 2025, 21:53 UTC

Earnings

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 gru 2025, 21:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

10 gru 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 gru 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 gru 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 gru 2025, 21:33 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 gru 2025, 21:32 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 gru 2025, 21:25 UTC

Earnings

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 gru 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 gru 2025, 21:16 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 gru 2025, 21:15 UTC

Earnings

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 gru 2025, 21:14 UTC

Earnings

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 gru 2025, 21:14 UTC

Earnings

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

3.49% upside

12 Months Forecast

Average 571.73 USD 3.49%

High 670 USD

Low 445 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

91 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.